Our understanding of the progression and mechanism underlying the onset of Parkinson's disease (PD) has grown enormously in the past few decades. There is growing evidence suggesting that poly (ADP-ribose) polymerase 1 (PARP-1) hyperactivation is involved in various neurodegenerative disorders, including PD, and that poly (ADP-ribose) (PAR)-dependent cell death is responsible for neuronal loss. In this review, we discuss the contribution of PARP-1 and PAR in the pathological process of PD. We describe the potential pathways regulated by the enzyme, review clinically relevant PARP-1 inhibitors as potential disease-modifying therapeutics for PD, and outline important factors that need to be considered for repurposing PARP-1 inhibitors for use in PD.

在过去的几十年里，我们对帕金森病 (PD) 发病的进展和机制的理解有了很大的提高。越来越多的证据表明多聚 (ADP-核糖) 聚合酶 1 (PARP-1) 过度激活与包括 PD 在内的各种神经退行性疾病有关，而多聚 (ADP-核糖) (PAR) 依赖性细胞死亡是神经元丢失的原因. 在这篇综述中，我们讨论了 PARP-1 和 PAR 在 PD 病理过程中的贡献。我们描述了由酶调节的潜在途径，回顾了临床相关的 PARP-1 抑制剂作为 PD 的潜在疾病缓解疗法，并概述了重新利用 PARP-1 抑制剂用于 PD 时需要考虑的重要因素。